drugset / Trial / NCT05302648
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Phase 0
Active not recruiting
18 enrolled
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2022-02-09
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Derived anti-BCMA CAR-T Injection | Cell therapy | 1e+06 cells | Other |
| Subject | Human Derived anti-BCMA CAR-T Injection | Cell therapy | 3e+06 cells | Other |
| Subject | Human Derived anti-BCMA CAR-T Injection | Cell therapy | 6e+06 cells | Other |